Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Wanda Forms Scientific Advisory Board

16 Mar 2016 07:00

RNS Number : 2148S
NetScientific PLC
16 March 2016
 

 

 

 ("NetScientific" or the "Group")

 

 

Wanda Forms Scientific Advisory Board to Provide Strategic Guidance

London, UK - 16 March 2016 - NetScientific plc (AIM: NSCI), the transatlantic biomedical and healthcare technology group, notes its Digital Health Portfolio company, Wanda, has announced the formation of a Scientific Advisory Board to provide thought leadership and strategic guidance to the Wanda management team. Board members include distinguished physicians, health economics scientists, and technologists committed to advancing clinical outcomes for individuals with chronic disease.

Commenting on the news, NetScientific's Chief Executive Officer, Francois R. Martelet said: "Wanda's technology has broad potential to simplify and improve the lives of people confronted with chronic conditions and, in the near term, to help patients with Congestive Heart Failure and their physicians to monitor risk and predict and prevent readmission to hospital. The calibre of the new SAB members is testament to the quality of the Wanda platform and we look forward to their input as Wanda develops into a world-leading digital health business."

The full text of the announcement issued by Wanda on 15 March 2016 can be found below:

 

Wanda Forms Scientific Advisory Board to Provide Strategic Guidance

 

Inaugural Members include clinical and technology experts committed to advancing the management of chronic disease

 

SAN FRANCISCO - March 15, 2016 Wanda today announced the formation of a Scientific Advisory Board to provide thought leadership and strategic guidance to the Wanda management team. Board members include distinguished physicians, health economics scientists, and technologists committed to advancing clinical outcomes for individuals with chronic disease.

 

"The inaugural members of Wanda's Scientific Advisory Board include an impressive mix of visionaries and opinion leaders across a variety of disciplines," said Wanda CCO Mark Heinemeyer. "All are passionate about advancing state-of-the-art chronic disease management."

 

"This group shares Wanda's belief in the power of excellent design to improve connections with patients, to engage loved ones, and to enhance outcomes," added Wanda CTO Foad Dabiri. "We look forward to working with these industry leaders as we continue to accelerate the development and implementation of the Wanda platform."

 

Wanda's new Scientific Advisory Board members include:

 

Constanzo DiPerna, MD, MBA - Dr. DiPerna is Medical Director of Dignity Health Cancer Institute of Greater Sacramento; Chief of Thoracic Surgery and Medical Director of Chest Disease for Mercy San Juan Medical Center; and Chief of Thoracic Surgery for Dignity Health Mercy Medical Group Sacramento. Dr. DiPerna is also the founder of ONCOVERSE LLC Global Center Network.

 

Clyde E. Wesp, Jr, MD, MAOM - Dr. West is Executive Clinical Strategist at Jacobus Consulting, where he is dedicated to improving the quality and safety of care along the continuum through clinical decision support, evidence-based medicine, and strategic transformation of clinical processes. He is currently a USC Adjunct Professor at the Sol Price School of Public Policy where he teaches Masters students in the area of population health and related clinical issues.

 

Janki Shah, MD - Dr. Shah is the founder and director of the UCLA Northwest Valley Women's Heart Health Program, which strives to ensure that women embrace cardiac screening and early detection of cardiovascular disease, as well as to provide a unique female focus on the education, prevention, early detection, treatment, and management of heart disease. Dr. Shah serves of the Board of Directors of the American Heart Association - Greater Los Angeles.

 

Jeff Moreland, BSN - Moreland is CEO and Chief Patient Officer for Patient Engagement Advisors (PEA). He created PEA as a self-funded effort, driven from the results of a Cleveland Clinic research project that considered the impact of care process gaps created when patients are transitioned across the healthcare continuum. Inc. Magazine has recognized PEA as one of the fastest growing companies in America and The American Business Awards has acknowledged PEA for its patient-focused technology innovation.

 

"Wanda is taking an innovative, science-based approach to solving some of healthcare's toughest and most longstanding problems," said Dr. Shah. "I am honored to serve on Wanda's Scientific Advisory Board and help the company improve the management of chronic disease."

 

Wanda's digital health platform connects the consumer and the clinical care team in a virtual network, intelligently collects critical vital and symptom information, and applies proven machine learning analytics to deliver ongoing risk analysis and decision support. Individuals are equipped to take better care of themselves and clinicians are able to more efficiently engage with those consumers when they need the most assistance maintaining a high quality of life at home.

 

The Wanda solution includes the unique easy-to-use Wanda app running on a smart phone or tablet. The app regularly interacts with an individual to simultaneously capture symptom information and to detect important vital sign measurements. Collected data is securely stored and analyzed on Wanda's cloud-based analytics platform, which utilizes machine learning to help individuals manage their health issues. Should intervention by a healthcare professional be required, Wanda identifies the appropriate provider to guide an appropriate intervention, avoiding potential deterioration of the individual's health condition that could result in disruptive and costly hospitalization.

 

# # #

 

About Wanda

 

San Francisco-based Wanda is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning in place of conventional technologies and by enabling clinicians to make more informed care decisions. Wanda recognizes that remote monitoring and algorithms cannot save lives or reduce hospitalizations unless the individual and their caregivers are promptly informed and highly engaged. Through the collaboration of data science and applied medical research, Wanda has proven that its inline analytics predict preventable events much better than conventional methods. Wanda serves as a diligent companion, providing encouragement and intelligent visual guidance that simplifies and improves lives, while simultaneously helping organizations reduce their care delivery costs. Wanda is a NetScientific portfolio company. More information about Wanda can be found HERE.

 

About NetScientific

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment.

 

For more information, please visit the website at www.netscientific.net

 

 

- Ends -

 

Contact Details

NetScientific

François R. Martelet, M.D., CEO

Mark Nanovich, Interim CFO

 

Tel: +44 (0)20 3514 1800

 

Investec (NOMAD and broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

 

Consilium Strategic Communications

Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton

 

Tel: +44 (0)20 3709 5700

Email: netscientific@consilium-comms.com

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRALFFIFVFIELIR
Date   Source Headline
30th Mar 20233:51 pmRNSPDS Update
28th Mar 20233:50 pmRNSPDS Business Update and 2022 Financial Results
28th Feb 20237:00 amRNSRelated party loan to ProAxsis Limited
27th Feb 20233:28 pmRNSPDS completes FDA meeting for triple combination
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 202311:05 amRNSSecond Price Monitoring Extn
10th Feb 202311:00 amRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSBoard Change
3rd Jan 20231:31 pmRNSPDS Announces Exclusive Global License Agreement
28th Dec 20223:05 pmRNSPDS Biotech: Median Overall Survival announcement
16th Dec 20227:00 amRNSPDS: HPV16 Head and Neck Cancer announcement
12th Dec 20222:00 pmRNSBoard Changes; Options; Co-Investment Agreement
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn
14th Nov 20222:00 pmRNSPrice Monitoring Extension
9th Nov 20227:00 amRNSBoard Change
7th Nov 20223:40 pmRNSPDS reports presentation of data at cancer society
20th Oct 20227:00 amRNSEMV Capital secures investment in Ventive
11th Oct 20224:00 pmRNSPDS Update
3rd Oct 20221:56 pmRNSPDS completes End-of-Phase 2 meeting with FDA
30th Sep 20227:00 amRNSHalf-year Report
25th Aug 20227:00 amRNSPDS Completes $35 Million Financing Agreement
16th Aug 20227:00 amRNSAcquisition of 30% Vortex stake & new Vortex CEO
8th Aug 20224:45 pmRNSPDS Reports Q2 2022 Results & Business Update
29th Jun 20222:05 pmRNSResult of AGM
28th Jun 20229:15 amRNSHolding(s) in Company
27th Jun 20228:30 amRNSDirector/PDMR Shareholding
27th Jun 20228:30 amRNSHolding(s) in Company
22nd Jun 20227:00 amRNSResult of Placing and Total Voting Rights
21st Jun 20224:41 pmRNSProposed Placing to raise at least £1.5 million
17th Jun 202212:00 pmRNSNetScientific to increase Q-Bot stake to 23.7%
15th Jun 20227:00 amRNSQ-Bot secures £1.6m of investment to fund growth
7th Jun 202211:07 amRNSNotice of AGM and Annual Report & Accounts
6th Jun 20227:00 amRNSPDS Granted FDA Fast Track Designation for PDS0101
27th May 20222:39 pmRNSPDS Biotech - new data for ongoing clinical trials
19th May 20227:00 amRNSGeneral Counsel Strategic Hire & Grant of Options
16th May 20227:00 amRNSProAxsis Update
12th May 20227:00 amRNSFinal Results
11th May 20223:46 pmRNSPDS Reports Q1 2022 Results & Business Update
9th May 20227:00 amRNSNotice of Results & Investor Presentation
6th May 20227:00 amRNSAcquisition of 30% of Vortex Biotech Holdings
25th Apr 20222:05 pmRNSSecond Price Monitoring Extn
25th Apr 20222:00 pmRNSPrice Monitoring Extension
25th Apr 202211:05 amRNSSecond Price Monitoring Extn
25th Apr 202211:00 amRNSPrice Monitoring Extension
31st Mar 20221:24 pmRNSPDS Provides Business Update & Full-Year Results
4th Mar 20227:30 amRNSPublication of Shareholder Newsletter
24th Feb 20224:45 pmRNSPDS Announces Preliminary Safety Data on PDS0101

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.